… 2) to test whether they can be used as biomarkers for PD diagnosis as well as its progression, including development … demonstrating high sensitivity and specificity in PD diagnosis and progression will be developed into to be more user friendly for practical use. Relevance …

… of prasinezumab announced this week that the drug is moving into the critical, Phase III stage of clinical trials. If … of people — usually in the thousands. During this trial, researchers gauge a drug’s effectiveness, side effects and … testing following two Phase II trials that demonstrated early signs of promise. The PADOVA trial tested the drug in …

… are some of the symptoms that can arise years after diagnosis with Parkinson’s disease (PD). Karen Jaffe, MD, … Marc Jaffe, Karen’s husband; writer, author and Parkinson’s research advocate.  Want to see the slides and other …

… disease (PD). Analyzing tissue taken during colonoscopies, researchers found the protein alpha-synuclein in the nerve … , MD, MSc. “Since 1997, this protein has been one of the PD research community’s major targets for developing new … Heiko Braak , MD, is tied to two symptoms that may signal early Parkinson’s: loss of smell and constipation. If it’s …

… This grant builds upon the research from a prior grant: rAAV-ribozyme Mediated Parkin … This project is designed to test 1) Does doxycyline cross into the primate brain? And 2) if so, can we turn off gene … step forward in developing a regulated GDNF treatment for early stage PD. Anticipated Outcome :  We have data that the …

… About Us:  The Michael J. Fox Foundation for Parkinson’s Research (MJFF) was founded in 2000 with a single defined … triple-pronged, singularly-defined strategy towards disease research enables a dynamic, motivated, and young organization. MJFF has quickly grown into the largest global funder of Parkinson’s disease …